Session date: 
10/26/2017 - 12:00pm to 1:00pm
Title: Pupils and Anisocoria

Presenter: Scott Mihalovic Pharm. D.

  • Relevant financial relationships: None
  • Off-label/ Investigational Uses: Yes
    • Manufacturers: CSL Behring, Boehringer-Ingleheim, Janssen, Bristol-Myers Squibb, Daiichi-Sankyo
    • Products: Kceentra, Dabigatran, Rivaroxaban, Apixaban, Edoxaban

Learning Objectives:

  • Identify the FDA approved indications for the new oral anticoagulant medications
  • Indicate common peri-procedural management strategies for the new oral anticoagulant medications
  • Indicate the appropriate reversal agents for the new oral anticoagulant medications.

Course Directors:

Dr. Cheri Olson
Relevant financial relationships: None
Off-Label/ Investigational Uses: None
                     
Dr. Greg Pupillo
Relevant financial relationships: None
Off-Label/ Investigational Uses: None
 
Course Coordinator:
Emily Sather, Stroke Coordinator
Relevant financial relationships: None
Off-Label/ Investigational Uses: None
 
Presenter: 
Scott Mihalovic
Additional presenter: 
Emily Sather, Stroke Coordinator
Where did the idea for the course originate?: 
Minnesota
Please login or register to take this course.
Where did the idea for the course originate?: 
Minnesota